251 related articles for article (PubMed ID: 32133742)
1. Targeting USP1-dependent KDM4A protein stability as a potential prostate cancer therapy.
Cui SZ; Lei ZY; Guan TP; Fan LL; Li YQ; Geng XY; Fu DX; Jiang HW; Xu SH
Cancer Sci; 2020 May; 111(5):1567-1581. PubMed ID: 32133742
[TBL] [Abstract][Full Text] [Related]
2. Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
Zhang B; Zhang M; Yang Y; Li Q; Yu J; Zhu S; Niu Y; Shang Z
Oncogene; 2022 Jan; 41(3):387-399. PubMed ID: 34759344
[TBL] [Abstract][Full Text] [Related]
3. Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.
Fan L; Peng G; Sahgal N; Fazli L; Gleave M; Zhang Y; Hussain A; Qi J
Oncogene; 2016 May; 35(19):2441-52. PubMed ID: 26279298
[TBL] [Abstract][Full Text] [Related]
4. KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.
Qiu MT; Fan Q; Zhu Z; Kwan SY; Chen L; Chen JH; Ying ZL; Zhou Y; Gu W; Wang LH; Cheng WW; Zeng J; Wan XP; Mok SC; Wong KK; Bao W
Oncotarget; 2015 Oct; 6(31):31702-20. PubMed ID: 26397136
[TBL] [Abstract][Full Text] [Related]
5. ETS transcription factor ERG cooperates with histone demethylase KDM4A.
Kim TD; Shin S; Janknecht R
Oncol Rep; 2016 Jun; 35(6):3679-88. PubMed ID: 27109047
[TBL] [Abstract][Full Text] [Related]
6. Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer.
Ponnusamy S; He Y; Hwang DJ; Thiyagarajan T; Houtman R; Bocharova V; Sumpter BG; Fernandez E; Johnson D; Du Z; Pfeffer LM; Getzenberg RH; McEwan IJ; Miller DD; Narayanan R
Clin Cancer Res; 2019 Nov; 25(22):6764-6780. PubMed ID: 31481513
[TBL] [Abstract][Full Text] [Related]
7. MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
Mu H; Xiang L; Li S; Rao D; Wang S; Yu K
J Cell Biochem; 2019 Apr; 120(4):4987-4997. PubMed ID: 30302800
[TBL] [Abstract][Full Text] [Related]
8. A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance.
Liao Y; Liu Y; Shao Z; Xia X; Deng Y; Cai J; Yao L; He J; Yu C; Hu T; Sun W; Liu F; Tang D; Liu J; Huang H
Oncogene; 2021 Jun; 40(25):4291-4306. PubMed ID: 34079090
[TBL] [Abstract][Full Text] [Related]
9. Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Kim TD; Jin F; Shin S; Oh S; Lightfoot SA; Grande JP; Johnson AJ; van Deursen JM; Wren JD; Janknecht R
J Clin Invest; 2016 Feb; 126(2):706-20. PubMed ID: 26731476
[TBL] [Abstract][Full Text] [Related]
10. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitin-mediated proteasomal degradation.
Tan MK; Lim HJ; Harper JW
Mol Cell Biol; 2011 Sep; 31(18):3687-99. PubMed ID: 21768309
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis.
Monga J; Subramani D; Bharathan A; Ghosh J
Sci Rep; 2020 Apr; 10(1):6649. PubMed ID: 32313135
[TBL] [Abstract][Full Text] [Related]
12. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
Wang J; Wang H; Wang LY; Cai D; Duan Z; Zhang Y; Chen P; Zou JX; Xu J; Chen X; Kung HJ; Chen HW
Cell Death Differ; 2016 Nov; 23(11):1886-1896. PubMed ID: 27612013
[TBL] [Abstract][Full Text] [Related]
13. Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Tang DE; Dai Y; He JX; Lin LW; Leng QX; Geng XY; Fu DX; Jiang HW; Xu SH
J Pathol; 2020 Oct; 252(2):101-113. PubMed ID: 32617978
[TBL] [Abstract][Full Text] [Related]
14. USP1 (ubiquitin specific peptidase 1) targets ULK1 and regulates its cellular compartmentalization and autophagy.
Raimondi M; Cesselli D; Di Loreto C; La Marra F; Schneider C; Demarchi F
Autophagy; 2019 Apr; 15(4):613-630. PubMed ID: 30335599
[TBL] [Abstract][Full Text] [Related]
15. Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.
Zhao J; Li B; Ren Y; Liang T; Wang J; Zhai S; Zhang X; Zhou P; Zhang X; Pan Y; Gao F; Zhang S; Li L; Yang Y; Deng X; Li X; Chen L; Yang D; Zheng Y
Exp Mol Med; 2021 Aug; 53(8):1207-1217. PubMed ID: 34385569
[TBL] [Abstract][Full Text] [Related]
16. AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
Liu C; Yang JC; Armstrong CM; Lou W; Liu L; Qiu X; Zou B; Lombard AP; D'Abronzo LS; Evans CP; Gao AC
Mol Cancer Ther; 2019 Oct; 18(10):1875-1886. PubMed ID: 31308078
[TBL] [Abstract][Full Text] [Related]
17. The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
Wilson S; Fan L; Sahgal N; Qi J; Filipp FV
Oncotarget; 2017 May; 8(18):30328-30343. PubMed ID: 28416760
[TBL] [Abstract][Full Text] [Related]
18. Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Lapidot M; Case AE; Weisberg EL; Meng C; Walker SR; Garg S; Ni W; Podar K; Hung YP; Carrasco RD; Knott A; Gokhale PC; Sharma S; Pozhitkov A; Kulkarni P; Frank DA; Salgia R; Griffin JD; Saladi SV; Bueno R; Sattler M
Br J Cancer; 2021 Aug; 125(4):582-592. PubMed ID: 34088988
[TBL] [Abstract][Full Text] [Related]
19. KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
Gao L; Zhang W; Zhang J; Liu J; Sun F; Liu H; Hu J; Wang X; Wang X; Su P; Chen S; Qu S; Shi B; Xiong X; Chen W; Dong X; Han B
Cancer Res; 2021 Feb; 81(4):1026-1039. PubMed ID: 33277366
[TBL] [Abstract][Full Text] [Related]
20. PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer.
Puhr M; Hoefer J; Eigentler A; Dietrich D; van Leenders G; Uhl B; Hoogland M; Handle F; Schlick B; Neuwirt H; Sailer V; Kristiansen G; Klocker H; Culig Z
Oncogene; 2016 May; 35(18):2322-32. PubMed ID: 26257066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
